Article Text

other Versions

PDF
Correspondence
Letter in response to TB during TNF-α inhibitor therapy, despite screening
  1. K Manalan,
  2. A Singanayagam,
  3. M Wickremasinghe,
  4. O M Kon
  1. Correspondence to Professor Onn Min Kon, Chest and Allergy Department, St Mary's Hospital, Imperial College Healthcare NHS Trust, London W2 1NY, UK; Onn.Kon{at}imperial.nhs.uk

Statistics from Altmetric.com

We read the case-based discussion published in Thorax by Hofland et al1 with great interest. The case studies reported by the authors raise a very important point about the necessity for continued monitoring of patients on tumour necrosis factor (TNF)-α antagonist therapy, even in the absence of evidence of latent TB infection (LTBI) at the onset of therapy and this is a point that is not discussed in the most recent British Thoracic society (BTS) guidance document on TB and anti-TNF α treatment.2

The two cases described in the article would be classified as ‘low risk’ and thus not offered chemoprophylaxis if managed according to current BTS recommendations. …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles